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Aim. The purpose of this article is to provide an overview of current insights into the 
neurodevelopmental and psychiatric manifestations of 22q11.2 deletion syndrome (22q11DS) in 
children and adolescents.  
Recent findings. The pediatric neuropsychiatric expression of 22q11DS is characterized by high 
variability, both inter-individual and intra-individual (different expressions over the lifespan). Besides 
varying levels of intellectual disability, the prevalence of autism spectrum disorders, attention deficit 
disorders, anxiety disorders, and psychotic disorders in young individuals with 22q11DS is significantly 
higher than in the general population, or in individuals with idiopathic intellectual disability. Possible 
explanations for this observed phenotypic variability will be discussed, including genetic pleiotropy, 
gene-environment interactions, the age-dependency of phenotypes, but also the impact of assessment 
and ascertainment bias as well as the limitations of our current diagnostic classification system.  
Implications. The implications inferred by these  observations mentioned above bear direct relevance to 
both scientists and clinicians. Observations regarding the neuropsychiatric manifestations in individuals 
with 22q11DS exemplify the need for a dimensional approach to neuropsychiatric assessment, in 
addition to our current categorical diagnostic classification system. The potential usefulness of 22q11DS 
as a genetic model to study the early phases of schizophrenia as well as the phenomenon of 
neuropsychiatric pleiotropy observed in many CNV’s will be delineated. From a clinical perspective, the 
importance of regular neuropsychiatric evaluations with attention to symptoms not always captured in 
diagnostic categories and of maintaining equilibrium between individual difficulties and competencies 
and environmental demands will be discussed.  
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Ever since the first reports of psychotic disorders in individuals with the 22q11.2 deletion 
(22q11DS) were published, now some 25 years ago, there has been increasing interest in this remarkable 
association[Bassett and others 1998; Murphy and others 1999; Pulver and others 1994; Shprintzen and 
others 1992]. These initial findings have been replicated in several studies, confirming an approximately 
25-fold increased risk of developing schizophrenia in patients with 22q11DS compared to a ~1% 
lifetime risk in the general population[McGrath and others 2008]. Understandably, this observed 
association continues to receive much attention from both clinicians and investigators. From a clinical 
perspective the increased risk mandates careful monitoring of patients, in particular during adolescence 
and early adulthood, when the risk of psychotic development is highest. From a research perspective the 
association represents the strongest known genetic risk for schizophrenia conferred by a single genetic 
variant[Van and others 2017]. In addition, the phenotypic expression of schizophrenia in 22q11DS has 
been described as indiscernible from schizophrenia in the general population[Bassett and others 2003; 
Chow and others 2006]. These observations have spurred the research community to examine 22q11DS 
as a unique genetically homogeneous model for schizophrenia {Gur, 2017 #5081}, and, in the words of 
Thomas Insel: initiate prospective studies of this population that will provide “important insights into the 
trajectory from risk to disorder”[Insel 2010].  
While the emphasis on schizophrenia and associated psychotic disorders (commonly referred to 
as “schizophrenia spectrum”) in 22q11DS is clearly justified[McDonald-McGinn and others 2015], a 
potential downside of a highly specific focus may be that the occurrence of other neuropsychiatric 
phenotypes in individuals with this genetic disorder can be easily overlooked. Multiple independent 
studies indicate significantly increased rates of a number of psychiatric and other neurodevelopmental 
disorders (including anxiety, autism spectrum, attention deficit disorders) in addition to schizophrenia in 
individuals with 22q11DS [Antshel and others 2006; Jolin and others 2009; Niklasson and others 2009; 
Schneider and others 2014a; Vorstman and others 2006]. This article will review the current knowledge 
of these phenotypes in 22q11DS, with a focus on childhood and adolescence. In addition, potential 
pitfalls regarding these findings will be examined, including the effect of ascertainment bias and 
possible limitations of categorical diagnostic classifications. Furthermore, both research and clinical care 
implications of the neuropsychiatric phenotypes in 22q11DS will be discussed.  
 
2. NEURODEVELOPMENTAL DISORDERS IN CHILDHOOD AND ADOLESCENCE 
2.1.1 Overview of the neuropsychiatric and cognitive phenotype  
The neurodevelopmental and psychiatric phenotype of children and adolescents with 22q11DS is 
highly diverse. From infancy onward, delayed and/or impaired speech and language development are 
frequently observed [Swillen and others 1999]. Moreover, intellectual functioning in the borderline 
range (FSIQ between 70-85) is most common, followed by mild intellectual disability (FSIQ 55-70). 
More severe levels of intellectual disability are uncommon in children, but more frequently observed in 
adults with 22q11DS[De Smedt and others 2007; Evers and others 2009; Swillen and others 1999] 
suggesting that cognitive abilities may not be stable in all individuals with 22q11DS. Indeed, a recent 
longitudinal study found that, overall, individuals with 22q11DS showed a modest but significant 
decline in IQ between the ages of 8 and 24[Vorstman and others 2015]. Notably, in those who 
developed a psychotic disorder, the decline, most pronounced in verbal IQ, was significantly steeper 
compared to those without a psychotic disorder. These findings provide evidence that cognitive decline 
might be a useful early clinical marker of psychotic disorders in people with 22q11DS[Vorstman and 
others 2015].  
 





***Figure 1: Prevalence of psychiatric disorders in 22q11DS from childhood to young adulthood*** 
 
The international brain and behavior consortium (IBBC) on 22q11DS has provided the most 
comprehensive overview of psychopathology in individuals with 22q11DS to date [Schneider and others 
2014a]. This first study from this multicenter consortium reported on the psychopathology of 1401 
individuals with 22q11DS, recruited across multiple sites, aged 6-68 (mean = 18,78, SD = 10,66) [Gur 
and others 2017; Schneider and others 2014a]. Figure 1 presents a summary of the findings across three 
different age groups between 6 and 25 years. Developmental disorders such as attention deficit 
hyperactivity disorder (ADHD) and autism spectrum disorder (ASD) are reported more frequently in the 
younger age groups as compared to the older groups (see also: [Antshel and others 2006; Niklasson and 
others 2009; Vorstman and others 2006]). Disruptive disorders are relatively less frequent overall, and 
their prevalence declines with increasing age. Mood disorders are frequently observed, and notably their 
prevalence increases significantly over time, particularly for major depressive disorder. Anxiety 
disorders are frequently reported across all age groups, but are especially prevalent in children and 
adolescents (see also: [Jolin and others 2009]). The prevalence of schizophrenia spectrum disorders 
increases significantly over time, with prevalence rates of 24% in emerging adults and about 41% in 
individuals over 25 years old (see also: [Bassett and others 2005; Murphy and others 1999]). 
 
2.1.2 The specificity of the psychiatric and neurodevelopmental profile in 22q11DS 
Observations from epidemiological studies indicate that the overall rate of psychopathology is 
increased in youth with idiopathic intellectual impairment [Einfeld and others 2011]. One particularly 
salient question therefore is to what extent the prevalence of psychiatric disorders in 22q11DS deviates 
from what is reported in unselected cohorts with intellectual impairment. Table 1 lists the prevalence 
rates of developmental and psychiatric disorders in individuals with 22q11DS (6 through 17 years) 
compared to observations in individuals with idiopathic intellectual impairment (n=641)[Emerson and 
Hatton 2007] and the general population.  
 
***Table 1: Prevalence rates of psychopathology in youth with 22q11DS compared to youth with 
idiopathic intellectual impairment and the general population*** 
 
It is important to note that prevalence rates reported in table 1 are all to some extent influenced 
by variable degrees of ascertainment and/or assessment biases and should therefore be compared with 
caution. For instance, individuals in the idiopathic intellectual impairment group were not recruited 
through a clinical site and intellectual impairment was established based on parental / teacher report. In 
contrast, many studies contributing to the overview of 22q11DS findings were conducted at a clinical 
site (see discussion below) and in many individuals IQ was obtained through formal testing. Rates 
reported in the general population are not specific for youth. 
Notwithstanding these precautions, some preliminary insights can be gained from table 1. First, 
from this young age onwards, psychotic disorders occur in the 22q11DS population (between age 13 and 
17 years the rate is already 10%). Many individuals fall into the diagnostic category “psychotic disorder 
not otherwise specified”, likely due to the young age at assessment. Second, the prevalence of other 
developmental disorders (ASD and ADHD) and mood/anxiety disorders is increased in 22q11DS youth 
over what is observed in a population with idiopathic intellectual impairment.  Third, the rate of 
disruptive disorders in people with 22q11DS is well below the rate in the idiopathic intellectual 
impairment population. These findings suggest that the 22q11.2 deletion has a specific impact on the 




behavioral phenotype and therefore that the risk of psychopathology cannot be solely explained as an 
unspecific consequence of intellectual impairment (Figure 2, scenario A).  
 
***Figure 2: Two possible associations between intellectual impairment and the increased risk for 
psychopathology in 22q11DS*** 
 
Further support for the proposition that the observed increased rates of psychopathology are specific to 
22q11DS (Figure 2, scenario B), as opposed to a non-specific effect of broad intellectual impairment, is 
provided by studies that show no correlation between cognitive level and the risk for psychiatric 
disorders in individuals with 22q11DS [Evers and others 2014; Niarchou and others 2014]. Accordingly, 
higher rates of psychopathology are reported in 22q11DS individuals compared to IQ-matched 
controls[Jansen and others 2007]. Inversely, the lower than expected prevalence rates of both disruptive 
disorders (albeit higher than in the general population, see Table 1) and substance use disorders in 
22q11DS (Vingerhoets et al. under review), compared to both general and idiopathic intellectually 
impaired populations [Carroll Chapman and Wu 2012; Swerts and others 2016] provide further evidence 
for a specific genetic effect. These findings suggest that scenario B (Figure 2) is likely  - although it does 
not exclude some effect by the mechanism of scenario A altogether. Furthermore, findings suggest that 
22q11DS increases the risk of some psychiatric disorders, but not of others. Indeed, similar to 
observations in cohorts with other structural pathogenic variants, emerging evidence indicates that 
specific profiles of psychopathology can be distinguished when comparing 22q11DS to idiopathic, 
unselected populations[Bruining and others 2014; Smith and others 2012].




2.2 Understanding the high degree of phenotypic variability  
2.2.1 Neuropsychiatric pleiotropy 
The psychiatric phenotypic expression of 22q11DS is highly variable. Many different psychiatric 
disorders are associated with this CNV, phenotypes can differ considerably between individuals, and 
differences exist across age groups. This variability is consistent with the phenomenon of phenotypic 
pleiotropy observed in many rare CNV’s [Bassett and others 2010; Vorstman and Ophoff 2013], 
whereby one specific genetic variant can result in independent phenotypic expressions. For example, in 
the context of 22q11DS, the presence or absence of congenital cardiac problems does not seem to be 
associated with an altered risk for psychotic disorders [Bassett and Chow 2008]. Therefore, congenital 
cardiac defects and psychotic disorders can be considered as true pleiotropic manifestations of the 
22q11.2 deletion. 
Observations from numerous studies suggest that in 22q11DS different psychiatric phenotypes 
can also emerge independently, as pleiotropic conditions. The distinction between true pleiotropy and 
“pseudopleiotropy” is important in this regard. The latter refers to phenotypes that are observed as 
separate manifestations, whereas in reality they represent the same pathological process, for instance at 
different developmental stages [Vorstman and others 2013]. Prospective longitudinal studies can provide 
insight in this regard. For example, a recent study found evidence for true pleiotropy regarding ASD and 
psychotic disorders, given that individuals with 22q11DS with ASD at a young age were not at an 
increased risk for developing psychotic disorders later in life compared to those without ASD [Fiksinski 
and others 2017] [Vorstman and others 2013]. On the other hand, cognitive decline [Duijff and others 
2012] and psychotic disorders in 22q11DS were initially reported as two different phenotypes, while 
subsequent prospective studies indicated that these two phenotypes represent, at least in a subset of 
individuals, the same pathological process but at different developmental stages [Vorstman and others 
2015], thereby providing an example of pseudopleiotropy. Such findings underline the importance of 
considering additional factors that may influence the observed phenotypic variability. Here, we will 
briefly discuss such factors, including the phenomena of gene-environment interactions, cross-site 
ascertainment and assessment differences, age-dependent phenotypes, and diagnostic classification 
artifacts that impact the observed comorbidity. 
 
2.2.2 Environmental factors as a source of inter-individual variability 
Several studies point towards the impact of environmental factors on the observed behavioral phenotype 
in individuals with 22q11DS. For example, studies have shown that lower parental socio-economic-
status (SES) and intrusive parenting style [Barber 2002] were associated with worse social functioning 
and other clinically significant problems in children with 22q11DS [Allen and others 2014; Shashi and 
others 2010]. Additional evidence is provided by a study examining the effect of Sept5 deficiency (one 
of the genes in the 22q11.2 region) on social functioning in a mice model of 22q11DS[Harper and others 
2012]. This study showed that Sept5 deficient mice had decreased affiliative social interactions 
compared to wild type mice. Interestingly, Sept5 deficient male mice exposed to individual housing 
were characterized by reduced anxiety and increased affiliative social interactions compared to mice 
exposed to group-housing, thereby showing a significant gene-environment interaction. Although more 
research is needed in this regard, such emerging evidence points to complex interactions between 
genetic and environmental factors as a source of phenotypic variability among individuals with 
22q11DS. 




2.2.3 Ascertainment and assessment bias 
The IBBC studies[Schneider and others 2014a] that contributed to the overview in Figure 1 
varied considerably in terms of ascertainment. Some sites are child psychiatry clinics, others are non-
clinical research settings and still others function primarily as adult specialty clinics. Studies conducted 
in clinical sites may bias against individuals with 22q11DS who function well, while clinical treatment 
may also reduce the “true natural” occurrence of psychiatric phenotypes in an untreated population. A 
recent epidemiological Danish nation-wide study of 22q11DS and 22q11.2 duplication syndrome offers 
a different perspective, as a population-based study. This study included 244 adult individuals with 
22q11DS identified through case registration in a population of 3,768,943.  The reported patterns of 
developmental and psychiatric disorders in 22q11DS, compared to 24,400 age- and gender-matched 
population controls, were similar to what is described in clinically ascertained 22q11DS cohorts, but, as 
expected, with somewhat lower prevalence rates [Hoeffding and others 2017]. 
The IBBC studies also varied with regard to the diagnostic assessment tools they employed and 
comorbid mental health problems screened [Schneider and others 2014a]. For example, not all sites used 
instruments to assess at risk status for psychotic disorders or standardized assessment for autism. 
Consequently, some of the differences in prevalence rates reported from different sites may be, at least 
partly, explained by differences in ascertainment and assessment (biases) across sites.  
 
2.2.4 Age-dependent phenotypes 
In individuals with 22q11DS, the variability observed across age groups can be inherent to 
phenotypic characteristics such as typical age of onset, consistent with observations in the general 
population. For example, in patient cohorts under the age of 18, one would not expect to find a high 
prevalence of schizophrenia spectrum disorders, as the first psychotic episode typically emerges in late 
adolescence/early adulthood [Owen and others 2016]. Differences in typically conducted psychiatric 
assessments across age groups may also contribute to the phenotypic variability reported across different 
ages. Standard adult psychiatric assessment often does not include screening for developmental 
disorders such as ASD or ADHD. In cohorts assessed as adults, one would therefore not expect to find a 
high prevalence of such developmental disorders, while in reality a portion of these individuals might 
have been diagnosed as such, had their psychiatric assessment – either as children or adults – included 
screening for these developmental disorders. With increasing awareness of ASD and ADHD in adults 
and associated clinical service developments however [Murphy and others 2016], the reported 
prevalence of ASD and ADHD in adults with 22q11DS may change in future reports.  
Not only can psychiatric conditions emerge as an individual matures, certain psychiatric 
disorders or neurodevelopmental presentations may also improve over time. Indeed, our clinical 
impression suggests that in some individuals with 22q11DS with a previous childhood 
neurodevelopmental diagnosis, improvement occurs to such extent that a diagnostic classification may 
no longer be justified in adulthood (e.g. ADHD or ASD), which is consistent with what is observed in 
idiopathic populations with such neurodevelopmental disorders (e.g.[Fein and others 2013; Woolfenden 
and others 2012] ). The finding that in a sample of 70 individuals with 22q11DS 30% of those 
previously diagnosed attention deficit disorder (ADD) did not manifest sufficient symptoms justifying 
an ADD diagnosis at follow-up assessment [Antshel and others 2010] provides preliminary evidence in 
this regard. Although such late-maturation trajectories are observed only in a minority of individuals 
with 22q11DS, they are relevant and warrant further study.  
 
 




2.2.5 The pitfalls of a categorical approach to the psychiatric phenotype in 22q11DS  
From both a clinical and a research perspective, employing a categorical diagnostic classification 
system has merits, as it provides clinicians and researchers with a shared vocabulary. However, a too 
stringent adherence to such a categorical, dichotomous approach to psychopathology also has substantial 
limitations. While this is relevant to all psychiatric populations, several observations in the 22q11DS 
population render the consideration of such potential limitations particularly salient for these 
individuals. On the one hand, it may result in the application of several diagnostic labels to account for a 
relatively small set of symptoms, while on the other hand clinically relevant but isolated symptoms may 
not readily fit in any diagnostic category and thus be overlooked [Baker and Vorstman 2012]. 
From a categorical perspective, a substantial portion of 22q11DS individuals is diagnosed with more 
than one psychiatric disorder [Jolin and others 2009; Schneider and others 2014a; Tang and others 
2014]. In addition, categorical classifications may be influenced by different interpretations of the same 
symptom domains. For instance, repetitive behaviors may be classified as an obsessive-compulsive 
disorder by one clinician, while the same symptoms in the same patient may be considered as part of an 
autistic spectrum disorder by another. The same diagnostic ambiguity may exist with regard to anxiety 
symptoms, which can justify an anxiety disorder but may not always be considered as such when 
occurring in the context of a psychotic disorder. Such ambiguities are inevitable as symptoms belonging 
to different diagnostic categories are frequently observed within the same individual with 22q11DS 
[Baker and Vorstman 2012]. Moreover, even in those children not meeting formal criteria for a 
psychiatric disorder, clinically relevant psychiatric symptoms are often present. Even within one 
symptom domain the use of categorical diagnoses may fall short in describing the reality of psychiatric 
symptoms with clinical relevance. For example, much higher prevalence rates of psychotic symptoms 
(25%) than of psychotic disorders (10%) are observed in adolescents with 22q11DS [Schneider and 
others 2016; Vorstman and others 2006]. Importantly, such symptoms, though not reflected in an 
individual’s psychiatric diagnosis, may still be relevant in understanding an individual’s profile of 
difficulties and competencies, as well as in implementing adequate treatment and preventive strategies. 
 
3. IMPLICATIONS FOR RESEARCH 
3.1  22q11DS as a genetic model for schizophrenia 
Several aspects of 22q11DS make this genetic disorder a highly appealing model to investigate 
neuroscientific questions, particularly the etiology of schizophrenia[Van and others 2017]. The highly 
increased risk for this illness in 22q11DS patients, and the opportunity to identify individuals early in 
life based on their genetic diagnosis has allowed investigators to study clinical and biological correlates 
of the developmental trajectory of schizophrenia. Moreover, a unique and easily overlooked aspect of 
these studies is that they are conducted in a genetically relatively homogeneous context, i.e. all 
individuals share the same 22q11.2 deletion, which can be assumed to be the cause of their high 
vulnerability for schizophrenia. In contrast, the broad and largely unknown genetic heterogeneity of 
schizophrenia hampers studies in unselected general population cohorts. Recent studies confirm the 
usefulness of 22q11DS as a human genetic model to unravel the gene x environment interactions leading 
to schizophrenia[Insel 2010]. Importantly, the psychopathological path leading to transition to psychosis 
in 22q11DS [Schneider and others 2016; Weisman and others 2017] is broadly comparable to that 
observed in other clinical high risk samples[Fusar-Poli and others 2013]. More specifically, the sub-
threshold psychotic symptoms and the Clinical High Risk (CHR) for psychosis criteria, previously 
developed in the general population[Fusar-Poli and others 2013], are reliable and also applicable in the 
22q11DS population.  
 





3.2 22q11DS exemplifies the need for dimensional and repeated assessment approaches  
Up until now, subclassifying individuals with 22q11DS by psychiatric diagnoses has not proven 
particularly useful in delineating underlying neurogenetic mechanisms. Indeed, it has been proposed that 
despite the divergence in diagnostic classifications, observations from different studies in 22q11DS 
converge into a limited number of symptom domains[Baker and Vorstman 2012].  Furthermore, 
preliminary associations have been described between genetic factors and symptoms dimensions that cut 
across existing diagnostic categories[Bassett and others 2007; Raux and others 2007; Shashi and others 
2006]. These and other studies underscore the potential added value of broad dimensional, quantitative 
and repeated assessments as a means towards a more dimensional perspective on mental health 
equilibrium and the risk of psychopathology[Nelson and others 2017].  
 
3.3 22q11DS as a model for neuropsychiatric pleiotropy in rare copy number variants 
The high variability of neuropsychiatric phenotypes observed in 22q11DS represents another 
unique research opportunity. The past decade has witnessed the discovery of a growing list of 
pathogenic genetic variants, including Copy Number Variants (CNVs)[Malhotra and Sebat 2012] and 
rare Single Nucleotide Variants (SNVs)[RK and others 2017]. Typically, the prevalence of each of these 
pathogenic variants is rare, but when present in an individual they can confer a substantial risk. The 
picture emerging from neuropsychiatric studies in individuals carrying these rare high impact variants is 
remarkably similar to what is observed in 22q11DS: a high degree of neuropsychiatric variability with 
increased rates of different disorders including schizophrenia, anxiety, ADHD, ASD and affective 
disorders and varying levels of cognitive impairment[Vorstman and Ophoff 2013]. Examples include, 
but are not limited to, the 3q29 deletion, which is associated with various neuropsychiatric disorders 
including anxiety and mood disorders and schizophrenia [Glassford and others 2016], and the 16p11.2 
deletion, associated with intellectual disability, ASD, and schizophrenia [Moreno-De-Luca and others 
2015]. Quantifying the risk of the different associated disorders and understanding how they emerge 
across the lifespan is essential to improve counseling and clinical care for individuals carrying these rare 
but high impact genetic variants[Vorstman and others 2017]. To this end, studies are needed to 
investigate for each of these rare pathogenic genetic variants to what extent there is true 
neuropsychiatric pleiotropy, the age-dependent emergence of certain phenotypes, and the possible 
influence of classification artifacts and ascertainment bias. In addition, it will be key to identify factors, 
both genetic and environmental, that modulate the different neuropsychiatric outcomes. Similarly, early 
phenotypic characteristics should be studied as potential markers for poor functional outcome. However, 
such studies are severely hampered by the fact that each of these variants occurs at extremely low rates 
in the population, impeding the collection of sufficiently powered samples.  
It is in this context that the 22q11.2 deletion syndrome provides a unique research opportunity. 
Its prevalence is high  (estimated 1/2,000-4,000)[McDonald-McGinn and others 2015] and its genetic 
description in the early 1980s[McDonald-McGinn and others 2015] has preceded by approximately two 
decades the much more recent discovery of the majority of other rare pathogenic genetic variants 
associated with psychiatric phenotypes[Malhotra and Sebat 2012]. This has afforded 22q11DS studies a 
significant advance over studies on other pathogenic variants. Indeed, at present, multiple cohorts of 
several hundreds of individuals with 22q11DS are examined in research institutes across the world. 
Findings of 22q11DS studies show the potential of using early phenotypic characteristics to identify 
subgroups with poor functional outcome[Schneider and others 2014b], and indicate several early 
potential biomarkers of psychotic disorder[Bakker and others 2016; Padula and others 2017; 
Ramanathan and others 2016; Raux and others 2007; Scariati and others 2016; Tomescu and others 




2014]. The IBBC [Gur and others 2017] has pooled phenotypic data from over 22 sites which together 
amount to well over 1,800 individuals with 22q11DS. This sample size, unprecedented in any other 
study on rare genetic variants with neuropsychiatric impact, allows the investigation of aforementioned 
questions with sufficient statistical power. 
 
4. IMPLICATIONS FOR CLINICAL CARE 
4.1 Need for regular psychiatric assessments 
International guidelines for clinical care for individuals with 22q11DS mandate regular 
psychiatric and cognitive assessment[Bassett and others 2011], understandably so, considering the 
overall high rates of psychopathology in this patient population. The observations reviewed in this 
article provide several directions in this regard. Psychiatric symptoms and disorders in 22q11DS may 
either remain constant over time, they may emerge or intensify  (e.g. psychotic disorders), or they may 
be outgrown and no longer be valid as individuals mature. Cognitive abilities may not be stable in a 
subgroup of patients and a decline in verbal IQ may indicate increased risk of developing a psychotic 
disorder[Vorstman and others 2015]. In order to maintain accuracy in describing an individual’s 
neuropsychiatric profile (and thereby allowing individualized mental healthcare) this time-related 
phenotypic variability needs to be considered and, consequently, repeated psychiatric and 
neuropsychological assessments are required.  
Emerging mental, rather than physical, health concerns are more likely to bring adolescents and 
young adults with 22q11DS to medical attention[Fung and others 2015; McDonald-McGinn and others 
2015; Schneider and others 2016; Swillen 2016]. Despite increasing awareness of the importance of 
planned transitions for young people with neurodevelopmental disorders to adult health and social 
care[Medicine. 2002; Stewart 2009; Young and others 2011], there is limited investigation of how best 
to do this[Belling and others 2014; Paul and others 2015] and future research is warranted. However, 
best practice guidelines for young people with 22q11DS should include a planned transition of mental 
health care (including psychiatric and cognitive assessments if resources allow) across different life 
stages and stressors. Examples include when moving from primary to secondary school and from 
adolescent to adult health care. 
With respect to all clinical recommendations for individuals with 22q11DS, including the need 
for regular psychiatric assessments and the importance of a guided transition to adulthood, there is the 
necessity to acknowledge, investigate and work towards overcoming the obstacles to implementing such 
recommendations. While there is consensus regarding the importance of discussing risk for psychiatric 
disorders in these individuals repeatedly throughout different stages of life [Bassett and others 2011; 
Hercher and Bruenner 2008], studies have reported that, for various possible reasons including stigma, 
other medical issues requiring attention and a young age at time of counseling, at present such 
discussions are insufficiently implemented in most clinical settings [Baughman and others 2015; Morris 
and others 2013]. 
 
4.2 Need to look beyond diagnostic categories 
Full-blown developmental and psychiatric disorders occur and may necessitate pharmacological 
or cognitive-behavioral therapeutic interventions in individuals with 22q11DS. However, the myriad of 
clinically relevant symptoms in these individuals is not always sufficiently captured in diagnostic 
classification categories. When symptoms are under-recognized or occur in isolation (i.e. in the absence 
of usually co-occurring symptoms critical for a diagnostic classification), they will not be reflected in an 
individual’s psychiatric diagnosis. Such symptoms may have significant impact on an individual’s daily 
functioning, but will remain unrecognized if only diagnostic categories are taken into account. In 




psychiatric assessments of individuals with 22q11DS, careful attention should therefore be paid not only 
to psychiatric diagnoses, but also to symptomatology as this may be important for lifestyle adaptations 
and professional care and (symptomatic) treatment. Taking symptom domains into consideration is 
pivotal in understanding an individual’s profile of competencies and difficulties[Baker and Vorstman 
2012; Beaton and Simon 2011]. Delineating such a profile is highly informative in finding and/or 
creating an environment that is optimally adapted to the individual. 
 
4.3 Emerging symptoms may represent imbalance abilities and demands; the importance of stress 
In all instances where severe psychopathology becomes manifest, adequate psychiatric treatment, 
often including pharmacological treatment, is required. In some instances where new symptoms emerge 
in a developing child, such as anxiety, depression, or psychosis, they appear to be related to an emerging 
discrepancy between the individual’s competencies and difficulties, and environmental demands. 
Clinically relevant psychiatric symptoms of mood, anxiety or psychosis may be indicative of a mismatch 
between an individual’s abilities and environmental demands and symptoms may improve when this 
balance is recovered. In some instances an accurate understanding of an individual’s neuropsychiatric 
phenotype, taking into consideration subclinical symptoms and fluctuations over time, allows for 
adequate and timely environmental adaptations, without exposing individuals to psychopharmacological 
compounds and their related side-effects. 
If a mismatch between an individual’s capacities and difficulties and their environmental 
demands exists for a prolonged period of time, the individual is likely to experience chronic stress. 
Stress has been identified as a risk factor for psychopathology in the general population[Sommer and 
others 2016] as well as a trigger to manifestation of a psychotic episode in idiopathic schizophrenia 
populations[Yui and others 1999]. Indeed, high levels of anxiety in youth with 22q11DS have been 
proposed as a predictor of transition to psychosis[Gothelf and others 2013], which supports the 
hypothesized importance of stress. In light of the 20-25% risk for developing schizophrenia and related 
psychotic disorders that individuals with 22q11DS have, optimal care should be taken to avoid stress. 
Creating and maintaining a balance between their neurocognitive, social and behavioral profile and 
environmental demands is essential in this regard.  
 
5. CONCLUSION 
The 22q11.2 deletion exemplifies the fast emerging novel class of rare pathogenic genetic 
variants as identifiable etiologies in the field of psychiatry, which raises important new challenges with 
immediate relevance for both researchers and clinicians. The early discovery of this rare CNV in the 
1980’s however, has allowed a time advantage over the majority of the other, more recently identified 
pathogenic rare variants.  Consequently, implications from studies on 22q11DS are not limited to this 
genetic disorder, but can also contribute to the understanding of phenomena observed in other rare 
pathogenic variants, including the high variability and variable expression of associated phenotypes.  
In addition to the well-established risk for schizophrenia, individuals with 22q11DS are at 
increased risk for a wide range of psychopathology from early childhood onwards. To some extent, this 
phenotypic variability may be an artifact of forcing the observed symptoms into our current diagnostic 
classifications. In addition, variable assessment and ascertainment methods are bound to further 
contribute to differences between studies. However, notwithstanding these caveats, several observations 
from 22q11DS studies begin to stand out.  
First, the prevalence of some pediatric psychiatric phenotypes, in particular anxiety, ASD, 
ADHD, and mood disorders, clearly exceeds what is observed in idiopathic ID. Together with the 
increased risk of schizophrenia in adolescents and (young) adults with 22q11DS, these observations 




strongly suggest a phenotypic effect that is specific to this genetic variant. Second, some 
neuropsychiatric phenotypes in 22q11DS are independent of others, indicating true pleiotropy, while 
others may represent time-dependent expressions of the same disease trajectory. Third, the disparity of 
reported phenotypes is mostly manifested in the limited framework of categorical diagnostic 
classifications. When focusing on the observed symptom domains, regardless of the classification used, 
a stronger coherence between different studies becomes readily apparent.  
The clinical implications follow from these observations. In any child with 22q11DS a thorough 
psychiatric evaluation is mandated, regardless of intellectual level.  Furthermore, expression of 
psychiatric phenotypes may vary over time even within the same individual, such as the decline in 
cognitive functioning observed in a subgroup of 22q11DS individuals. Taken together, these 
observations underline the importance of repeated clinical evaluations in this population. In the context 
of a genetic predisposition for developing schizophrenia, it is important to maintain an optimal balance 
between individual abilities and environmental expectations. A global low cognitive level (IQ), but also 
specific (and sometimes covert) relative weaknesses in cognitive domains and neurodevelopmental 
functions (e.g. attention, information processing, social and communicative abilities and sensitivity to 
sensory input) can contribute to chronic stress due to demands that exceed abilities. The clinical 
importance is twofold. First, such a situation is undesirable in itself as it causes discomfort and stress to 
any person. Second, numerous studies indicate that stress may play a role in the course of schizophrenia. 
While such evidence is not yet robustly available in the 22q11DS population, it is possible that in the 
context of a high genetic risk, high levels of stress may contribute to the expression of schizophrenia.  
The genetic predisposition for psychotic disorders conferred by 22q11DS provides strong 
impetus to obtain detailed insight into an individual’s cognitive and neurodevelopmental profile to avoid 
or reduce  (chronic) situations of stress. Interventions to correct such situations may have direct clinical 
impact but can also serve as a model to study the feasibility of primary and secondary intervention 
strategies in a population at risk for schizophrenia. However, the full scope of clinically relevant 
symptoms may often not be accurately represented in diagnostic classifications. Findings from studies in 
the 22q11DS population indicate that a dimensional, quantitative symptom assessment of 
psychopathology may be required in order to obtain the most accurate picture, both for clinical care and 
for scientific research.  
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Table 1: Prevalence rates of psychopathology in youth with 22q11DS compared to youth with idiopathic 
intellectual impairment and the general population 
 
 Youth with 
22q11DSa  
 
Youth with idiopathic 
intellectual 
impairmentb  
Youth in general 
populationc 
ADHD 32.1% 8.3% 5%I  
Disruptive disordersd 13.0% 20.5% 6%II 
ASD 21.5% 8.0% 1 – 1.5%III, IV 
Any mood disorder 7.0% 1.4% 10%II, V  
Any anxiety disorder 34.9% 11.4% 12%VI  
Any psychotic disorder, 
including schizophrenia  
5.5% not reported  << 1% VII, VIII, IX 
 
a Data from [Schneider and others 2014a] (805 individuals, note that percentages deviate from figure 1 since we 
collapsed data obtained in the age range 6 to 17 years, most individuals assessed at a level of mild intellectual 
disability) 
b Data from [Emerson and Hatton 2007] (641 individuals, age range 5 to 16 years, intellectual impairment based 
on parental/teacher report, most individuals estimated at a level of mild intellectual disability, the numbers 
represent point prevalence (i.e. symptoms present during the month – half year preceding the assessment)  
c Data from cohorts including both children and adolescents were used to obtain these estimates; exact age ranges 
vary between the different studies.  
d Oppositional defiant disorder, conduct disorder.  
I Polanczyk and others 2007; II Costello and others 2003; III Autism and others 2009; IV Developmental Disabilities 
Monitoring Network Surveillance Year Principal and others 2014; V Lipari and others 2013; VI Copeland and 
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